Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity

Neutralizing antibodies (inhibitors) to replacement Factor-VIII impair the effective management of hemophilia-A1. Individuals with hemophilia-A due to major F8 gene disruptions lack antigenically cross-reactive material in their plasma (CRM-negative) and prevalence of inhibitors is >60%. Converse...

Full description

Bibliographic Details
Main Authors: Pandey, Gouri Shankar, Yanover, Chen, Miller-Jenkins, Lisa M., Garfield, Susan, Cole, Shelley A., Curran, Joanne E., Moses, Eric K., Rydz, Natalia, Simhadri, Vijaya, Kimchi-Sarfaty, Chava, Lillicrap, David, Viel, Kevin, Przytycka, Teresa M., Pierce, Glenn F., Howard, Tom E., Sauna, Zuben E.
Format: Online
Language:English
Published: 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123441/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123441/

Similar Items